These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 38540686)

  • 1. SPINK1 Overexpression Correlates with Hepatocellular Carcinoma Treatment Resistance Revealed by Single Cell RNA-Sequencing and Spatial Transcriptomics.
    Yang C; Guo L; Du J; Zhang Q; Zhang L
    Biomolecules; 2024 Feb; 14(3):. PubMed ID: 38540686
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serine Protease Inhibitor Kazal Type 1, A Potential Biomarker for the Early Detection, Targeting, and Prediction of Response to Immune Checkpoint Blockade Therapies in Hepatocellular Carcinoma.
    Jia J; Ga L; Liu Y; Yang Z; Wang Y; Guo X; Ma R; Liu R; Li T; Tang Z; Wang J
    Front Immunol; 2022; 13():923031. PubMed ID: 35924241
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serine peptidase inhibitor Kazal type 1 (SPINK1) as novel downstream effector of the cadherin-17/β-catenin axis in hepatocellular carcinoma.
    Shek FH; Luo R; Lam BYH; Sung WK; Lam TW; Luk JM; Leung MS; Chan KT; Wang HK; Chan CM; Poon RT; Lee NP
    Cell Oncol (Dordr); 2017 Oct; 40(5):443-456. PubMed ID: 28631187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SPINK1-induced tumor plasticity provides a therapeutic window for chemotherapy in hepatocellular carcinoma.
    Man KF; Zhou L; Yu H; Lam KH; Cheng W; Yu J; Lee TK; Yun JP; Guan XY; Liu M; Ma S
    Nat Commun; 2023 Nov; 14(1):7863. PubMed ID: 38030644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overexpression of tumor-associated trypsin inhibitor (SPINK1/TATI) in hepatitis C-associated hepatocellular carcinoma: potential implications for viral hepatocarcinogenesis.
    Hass HG; Jobst J; Vogel U; Scheurlen M; Nehls O
    Oncol Res Treat; 2014; 37(12):732-8. PubMed ID: 25531719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High SPINK1 Expression Predicts Poor Prognosis and Promotes Cell Proliferation and Metastasis of Hepatocellular Carcinoma.
    Huang K; Xie W; Wang S; Li Q; Wei X; Chen B; Hua Y; Li S; Peng B; Shen S
    J Invest Surg; 2021 Sep; 34(9):1011-1020. PubMed ID: 32066292
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serine protease inhibitor Kazal type 1 (SPINK1) downregulates E-cadherin and induces EMT of hepatoma cells to promote hepatocellular carcinoma metastasis via the MEK/ERK signaling pathway.
    Ying HY; Gong CJ; Feng Y; Jing DD; Lu LG
    J Dig Dis; 2017 Jun; 18(6):349-358. PubMed ID: 28544403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinoma.
    Karkampouna S; van der Helm D; Gray PC; Chen L; Klima I; Grosjean J; Burgmans MC; Farina-Sarasqueta A; Snaar-Jagalska EB; Stroka DM; Terracciano L; van Hoek B; Schaapherder AF; Osanto S; Thalmann GN; Verspaget HW; Coenraad MJ; Kruithof-de Julio M
    J Pathol; 2018 Jul; 245(3):297-310. PubMed ID: 29604056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Diagnostic Role of SPINK1 in Differentiating Hepatocellular Carcinoma From Nonmalignant Lesions.
    Holah NS; El-Azab DS; Aiad HAE; Sweed DMM
    Appl Immunohistochem Mol Morphol; 2017; 25(10):703-711. PubMed ID: 27028242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Performance of SPINK1 and SPINK1-based diagnostic model in detection of hepatocellular carcinoma.
    Wang F; Liu H; Bai Y; Li H; Wang Z; Xu X
    J Clin Lab Anal; 2021 Nov; 35(11):e24025. PubMed ID: 34569662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased effects of 2,5-dimethylcelecoxib on sensitivity of hepatocellular carcinoma cells to sorafenib via CYP3A5 expression and activation of AMPK.
    Chen Y; Pan B; Qiu J; Chen Z; Wang X; Tang N
    Toxicol In Vitro; 2021 Oct; 76():105226. PubMed ID: 34293431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased Serum Levels of Trypsin Inhibitor Kazal1 in Patients with HBV-Related Hepatocellular Carcinoma Predict a Poor Prognosis.
    Yan RR; Zhu T; Wang Q; Yang K; Li J; Guan SH
    Clin Lab; 2021 Jan; 67(1):. PubMed ID: 33491427
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatitis B Virus X Protein-Induced Serine Protease Inhibitor Kazal Type 1 Is Associated with the Progression of HBV-Related Diseases.
    Zhu C; Han H; Li J; Xu L; Liu F; Wu K; Liu X
    Biomed Res Int; 2019; 2019():9321494. PubMed ID: 31240230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MAPK inhibitors induce serine peptidase inhibitor Kazal type 1 (SPINK1) secretion in BRAF V600E-mutant colorectal adenocarcinoma.
    Räsänen K; Dang KX; Mustonen H; Ho TH; Lintula S; Koistinen H; Stenman UH; Haglund C; Stenman J
    Mol Oncol; 2018 Feb; 12(2):224-238. PubMed ID: 29193645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ID1 promotes hepatocellular carcinoma proliferation and confers chemoresistance to oxaliplatin by activating pentose phosphate pathway.
    Yin X; Tang B; Li JH; Wang Y; Zhang L; Xie XY; Zhang BH; Qiu SJ; Wu WZ; Ren ZG
    J Exp Clin Cancer Res; 2017 Nov; 36(1):166. PubMed ID: 29169374
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oxaliplatin resistance is enhanced by saracatinib via upregulation Wnt-ABCG1 signaling in hepatocellular carcinoma.
    Liao X; Song G; Xu Z; Bu Y; Chang F; Jia F; Xiao X; Ren X; Zhang M; Jia Q
    BMC Cancer; 2020 Jan; 20(1):31. PubMed ID: 31931755
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuroblastoma RAS Viral Oncogene Homolog (NRAS) Is a Novel Prognostic Marker and Contributes to Sorafenib Resistance in Hepatocellular Carcinoma.
    Dietrich P; Gaza A; Wormser L; Fritz V; Hellerbrand C; Bosserhoff AK
    Neoplasia; 2019 Mar; 21(3):257-268. PubMed ID: 30685691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TAK1 Is a Novel Target in Hepatocellular Carcinoma and Contributes to Sorafenib Resistance.
    Xia S; Ji L; Tao L; Pan Y; Lin Z; Wan Z; Pan H; Zhao J; Cai L; Xu J; Cai X
    Cell Mol Gastroenterol Hepatol; 2021; 12(3):1121-1143. PubMed ID: 33962073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LncRNA LIMT (LINC01089) contributes to sorafenib chemoresistance via regulation of miR-665 and epithelial to mesenchymal transition in hepatocellular carcinoma cells.
    Sun J; Zheng X; Wang B; Cai Y; Zheng L; Hu L; Lu X; Xie S; Zhang X; Liu H; Ye L
    Acta Biochim Biophys Sin (Shanghai); 2022 Jan; 54(2):261-270. PubMed ID: 35130616
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy.
    Zhao Q; Zheng B; Meng S; Xu Y; Guo J; Chen LJ; Xiao J; Zhang W; Tan ZR; Tang J; Chen L; Chen Y
    Biomed Pharmacother; 2019 Jun; 114():108864. PubMed ID: 30981107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.